IDEXX Laboratories does everything right in first quarter!
Select language to see a machine translation of this article. The original language of the Article is English and the translation is provided for your convenience.

IDEXX Laboratories does everything right in first quarter!

IDEXX Laboratories, a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, reported a stellar set of figures for its first quarter. The company is exposed to the fast growing pet care trend among middle class consumers: newly affluent people around the world are taking better care of their animal companions, buying more expensive diagnostic treatments. The company’s last three months demonstrates the strong demand that IDEXX’s products are experiencing. Unsurprisingly, the company’s share price (which was already performing incredibly well) surged.

IDEXX’s share price has risen by 32% so far this year

idexx 110518

Source: Yahoo Finance

IDEXX said that it saw 16% growth in revenue from the same period in the previous year (12% organic), which was driven by strong performance (+17% year on year) in its CAG Diagnostics segment. It completed 2,822 premium instrument places, which the company described as a “record setting” first quarter, 21% better than the first quarter of 2017. The company reported earnings per share (EPS) of $1.01, saying in a press release that these earnings were “driven by high revenue growth, strong operating margin gains and net benefits from U.S. Tax Reform.”

As a result of the strong first part of the year, IDEXX maintained its revenue guidance, and increased its EPS outlook for full year 2018. The company now expects earnings between $4.06 and $4.20 (a 2¢ increase).

Jonathan Ayers, the company’s chairman and CEO, said: “We are pleased with the outstanding execution of our expanded commercial teams around the world in the first quarter, which resulted in 21% growth in premium instrument placements.  These results were fueled by our newest innovations, including SediVue Dx and the launch of the IDEXX Catalyst SDMA Test early in the quarter, which further add to the unique value provided by our point-of-care suite of instruments with real-time patient insight.”

“As we continue to advance our commercial presence, innovation and support for our customers, we are building our reputation as a partner in elevating the standard of care, which leads to both healthy practice growth and sustained organic volume gains by IDEXX.”

Disclosure
Dominion holds IDEXX Laboratories in its Global Trends Luxury Fund.


If you would you like to receive the Newsfeeds daily, please click here to sign up now!

Help us make this Newsfeed better by rating this article. 1 star = Poor and 5 stars = Excellent
0.0/5 rating (0 votes)

Disclaimer
The views expressed in this article are those of the author at the date of publication and not necessarily those of Dominion Fund Management Limited. The content of this article is not intended as investment advice and will not be updated after publication. Images, video, quotations from literature and any such material which may be subject to copyright is reproduced in whole or in part in this article on the basis of Fair use as applied to news reporting and journalistic comment on events.